Bumetanide is a prescription medication used to remove excess fluid caused by heart, liver, or kidney disease. Alzheimer’s prevention remains unproven; no demonstrated healthspan or lifespan gains support preventive use. Electrolyte loss, dehydration, kidney injury, and bone-density loss weigh against uncertain cognitive effects. Monitoring can identify some harms but cannot establish longevity benefit. (Full Review)
| Marker | Target | Why |
|---|---|---|
| Potassium | 3.5–5.0 mmol/L | Depletion and rhythm risk |
| Sodium | 135–145 mmol/L | Water/salt imbalance |
| Magnesium | 1.7–2.2 mg/dL | Depletion and rhythm risk |
| Chloride | 98–107 mmol/L | Salt loss |
| Bicarbonate | 22–29 mmol/L | Acid–base change |
| Creatinine | No established target; baseline and trend | Kidney function |
| Estimated filtration rate | No established target; baseline and trend | Kidney function |
| Blood urea nitrogen | No established target; baseline and trend | Depletion/kidney impairment |
| Uric acid | No established target; change and gout symptoms | Uric acid retention |
| Fasting glucose | 70–99 mg/dL | Glucose disturbance |
| Bone density when prolonged exposure and baseline risk justify testing | No established target; change from baseline | Bone loss |
| Blood pressure | No established target; individual baseline and symptoms | Safety and fluid-removal response |
| Bodyweight | No established target; individual baseline and symptoms | Safety and fluid-removal response |
Cadence: Common practice, not trial-validated for longevity: baseline; electrolytes and kidney function at 3–7 days after initiation or dose change, 2–4 weeks, then every 3–6 months when stable; earlier with illness or symptoms. Weight and blood pressure during adjustment. Glucose follows the diabetes monitoring plan; bone density follows the individual bone-health plan.